Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
| Revenue (Most Recent Fiscal Year) | $69.65M |
| Net Income (Most Recent Fiscal Year) | $-81.27M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 9.89 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.24 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -116.66% |
| Net Margin (Trailing 12 Months) | -116.69% |
| Return on Equity (Trailing 12 Months) | -39.13% |
| Return on Assets (Trailing 12 Months) | -29.31% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.76 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.61 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 10.19 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.94 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.26 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.91 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.91 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 104.63M |
| Free Float | 100.66M |
| Market Capitalization | $688.48M |
| Average Volume (Last 20 Days) | 1.62M |
| Beta (Past 60 Months) | 2.20 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 61.91% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |